Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1993 Sep;68(3):457–459. doi: 10.1038/bjc.1993.369

Surrogate endpoints.

S S Ellenberg
PMCID: PMC1968384  PMID: 8353034

Full text

PDF
457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  2. Bergsagel D. E., Bailey A. J., Langley G. R., MacDonald R. N., White D. F., Miller A. B. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979 Oct 4;301(14):743–748. doi: 10.1056/NEJM197910043011402. [DOI] [PubMed] [Google Scholar]
  3. Boice J. D., Jr, Greene M. H., Killen J. Y., Jr, Ellenberg S. S., Keehn R. J., McFadden E., Chen T. T., Fraumeni J. F., Jr Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983 Nov 3;309(18):1079–1084. doi: 10.1056/NEJM198311033091802. [DOI] [PubMed] [Google Scholar]
  4. Byar D. P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973 Nov;32(5):1126–1130. doi: 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  5. Choi S., Lagakos S. W., Schooley R. T., Volberding P. A. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993 May 1;118(9):674–680. doi: 10.7326/0003-4819-118-9-199305010-00003. [DOI] [PubMed] [Google Scholar]
  6. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. doi: 10.1016/0140-6736(90)90944-z. [DOI] [PubMed] [Google Scholar]
  7. Coltman C. A., Jr, Dixon D. O. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep. 1982 Apr;66(4):1023–1033. [PubMed] [Google Scholar]
  8. Dahlöf B., Lindholm L. H., Hansson L., Scherstén B., Ekbom T., Wester P. O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991 Nov 23;338(8778):1281–1285. doi: 10.1016/0140-6736(91)92589-t. [DOI] [PubMed] [Google Scholar]
  9. Ellenberg S. S. Surrogate end points in clinical trials. BMJ. 1991 Jan 12;302(6768):63–64. doi: 10.1136/bmj.302.6768.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ellenberg S., Hamilton J. M. Surrogate endpoints in clinical trials: cancer. Stat Med. 1989 Apr;8(4):405–413. doi: 10.1002/sim.4780080404. [DOI] [PubMed] [Google Scholar]
  11. Gerber G. S., Chodak G. W. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol. 1990 Nov;144(5):1177–1179. doi: 10.1016/s0022-5347(17)39685-4. [DOI] [PubMed] [Google Scholar]
  12. Jacobson M. A., Bacchetti P., Kolokathis A., Chaisson R. E., Szabo S., Polsky B., Valainis G. T., Mildvan D., Abrams D., Wilber J. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991 Jan 12;302(6768):73–78. doi: 10.1136/bmj.302.6768.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lagakos S. W., Hoth D. F. Surrogate markers in AIDS: where are we? Where are we going? Ann Intern Med. 1992 Apr 1;116(7):599–601. doi: 10.7326/0003-4819-116-7-599. [DOI] [PubMed] [Google Scholar]
  14. Lavin P. T., Flowerdew G. Studies in variation associated with the measurement of solid tumors. Cancer. 1980 Sep 1;46(5):1286–1290. doi: 10.1002/1097-0142(19800901)46:5<1286::aid-cncr2820460533>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  15. Machado S. G., Gail M. H., Ellenberg S. S. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr. 1990;3(11):1065–1073. [PubMed] [Google Scholar]
  16. Moertel C. G., Hanley J. A. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976 Jul;38(1):388–394. doi: 10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  17. Reimer R. R., Hoover R., Fraumeni J. F., Jr, Young R. C. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. doi: 10.1056/NEJM197707282970402. [DOI] [PubMed] [Google Scholar]
  18. Scher H. I., Curley T., Yeh S., Iversen J. M., O'Dell M., Larson S. M. Therapeutic alternatives for hormone-refractory prostatic cancer. Semin Urol. 1992 Feb;10(1):55–64. [PubMed] [Google Scholar]
  19. Seidman A. D., Scher H. I., Petrylak D., Dershaw D. D., Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992 Mar;147(3 Pt 2):931–934. doi: 10.1016/s0022-5347(17)37426-8. [DOI] [PubMed] [Google Scholar]
  20. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  21. Taylor J. M., Fahey J. L., Detels R., Giorgi J. V. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr. 1989;2(2):114–124. [PubMed] [Google Scholar]
  22. Warr D., McKinney S., Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984 Sep;2(9):1040–1046. doi: 10.1200/JCO.1984.2.9.1040. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES